Colorectal Cancer Specialty Channel

Colorectal Cancer

Specialty Channel

News

Neoadjuvant Nivolumab Plus Ipilimumab Showed Promise Among Patients With Locally Advanced Mismatch-Repair Deficient Colon Cancer

07/18/2024

Stephanie Holland ;

According to results from the phase 2 NICHE-2 trial, neoadjuvant nivolumab plus ipilimumab showed promise among patients with locally advanced mismatch repair-deficient colon cancer.

According to results from the...

07/18/2024

Oncology

News

Lenvatinib Plus Pembrolizumab Did Not Significantly Improve Overall Survival Among Patients With pMMR or Not MSI-High Metastatic Colorectal Cancer

07/11/2024

Stephanie Holland ;

Final analysis results from the phase 3 LEAP-017 trial demonstrated that lenvatinib plus pembrolizumab did not significantly improve overall survival compared to standard of care among patients with previously treated mismatch repair...

Final analysis results from the...

07/11/2024

Oncology

News

FDA Grants Accelerated Approval to Adagrasib With Cetuximab for Patients With KRAS G12C-Mutated Colorectal Cancer

06/21/2024

Based on results from the KRYSTAL-1 trial, the FDA has granted accelerated approval to adagrasib with cetuximab for patients with KRAS G12C-mutated colorectal cancer.

Based on results from the...

06/21/2024

Oncology

Martijn Meijerink, MD, PhD, Amsterdam UMC

Videos

Thermal Ablation Non-Inferior to Surgery for Patients With Smaller Colorectal Liver Metastases

06/19/2024

Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.

Martijn Meijerink, MD, PhD,...

06/19/2024

Oncology

Conference Coverage

Ipilimumab Biosimilar Added to Sintilimab in Neoadjuvant Setting Improves Response Rates Among Patients With MSI-H/dMMR Colorectal Cancer

05/28/2024

Allison Casey

According to results from a phase 1b study, the addition of an ipilimumab biosimilar (IBI310) to sintilimab in the neoadjuvant setting improved pCR rates among patients with locally advanced, resectable microsatellite...

According to results from a...

05/28/2024

Oncology

News

Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors

05/17/2024

Stephanie Holland

Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...

Results from the ORANGE II PLUS...

05/17/2024

Oncology

News

Potential Benefits From Neoadjuvant Chemotherapy for Patients With Locally Advanced Colon Cancer

04/09/2024

Stephanie Holland

Results from the phase 3 OPTICAL study found potential benefits from neoadjuvant mFOLFOX6 or CAPOX among patients with locally advanced colon cancer.

Results from the phase 3 OPTICAL...

04/09/2024

Oncology

News

FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-Positive Solid Tumors

04/08/2024

Stephanie Holland

The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.

The FDA granted accelerated...

04/08/2024

Oncology

Thierry André, MD, Saint Antoine Hospital

Videos

Nivolumab Plus Ipilimumab Yields Superior PFS vs Chemotherapy for First-Line Treatment of Metastatic Colorectal Cancer

01/23/2024

Featuring Thierry André, MD

Thierry Andre, MD, discusses the first results from the CheckMate 8HW study exploring nivolumab plus chemotherapy for the first-line treatment of microsatellite instability-high, mismatch repair-deficient metastatic colorectal cancer.

Thierry Andre, MD, discusses the...

01/23/2024

Oncology

Jeanne Tie, MBChB, MD, Peter MacCallum Cancer Centre

Videos

Circulating Tumor DNA-Guided vs Standard Management of Locally Advanced Rectal Cancer

01/20/2024

Featuring Jeanne Tie, MBChB, MD

Featuring Jeanne Tie, MBChB, MD ...

Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.

Professor Jeanne Tie, MBChB,...

01/20/2024

Oncology

Conference Coverage

Significance of ctDNA Clearance Following Adjuvant Chemotherapy Among Patients with Radically Resected Colorectal Cancer

01/20/2024

Allison Casey

According to updated results from a substudy of the observational GALAXY study, detection of MRD via ctDNA and ctDNA dynamics in response to adjuvant chemotherapy for colorectal cancer were found to be highly prognostic of patient outcomes in...

According to updated results...

01/20/2024

Oncology

News

Neoadjuvant Nivolumab Plus Ipilimumab Showed Promise Among Patients With Locally Advanced Mismatch-Repair Deficient Colon Cancer

07/18/2024

Stephanie Holland ;

According to results from the phase 2 NICHE-2 trial, neoadjuvant nivolumab plus ipilimumab showed promise among patients with locally advanced mismatch repair-deficient colon cancer.

According to results from the...

07/18/2024

Oncology

News

Lenvatinib Plus Pembrolizumab Did Not Significantly Improve Overall Survival Among Patients With pMMR or Not MSI-High Metastatic Colorectal Cancer

07/11/2024

Stephanie Holland ;

Final analysis results from the...

07/11/2024

Oncology

News

FDA Grants Accelerated Approval to Adagrasib With Cetuximab for Patients With KRAS G12C-Mutated Colorectal Cancer

06/21/2024

Based on results from the KRYSTAL-1 trial, the FDA has granted accelerated approval to adagrasib with cetuximab for patients with KRAS G12C-mutated colorectal cancer.

Based on results from the...

06/21/2024

Oncology

Videos

Thermal Ablation Non-Inferior to Surgery for Patients With Smaller Colorectal Liver Metastases

06/19/2024

Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.

Martijn Meijerink, MD, PhD,...

06/19/2024

Oncology

Conference Coverage

Ipilimumab Biosimilar Added to Sintilimab in Neoadjuvant Setting Improves Response Rates Among Patients With MSI-H/dMMR Colorectal Cancer

05/28/2024

Allison Casey

According to results from a...

05/28/2024

Oncology

News

Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors

05/17/2024

Stephanie Holland

Results from the ORANGE II PLUS...

05/17/2024

Oncology

News

Potential Benefits From Neoadjuvant Chemotherapy for Patients With Locally Advanced Colon Cancer

04/09/2024

Stephanie Holland

Results from the phase 3 OPTICAL study found potential benefits from neoadjuvant mFOLFOX6 or CAPOX among patients with locally advanced colon cancer.

Results from the phase 3 OPTICAL...

04/09/2024

Oncology

News

FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-Positive Solid Tumors

04/08/2024

Stephanie Holland

The FDA granted accelerated...

04/08/2024

Oncology

Videos

Nivolumab Plus Ipilimumab Yields Superior PFS vs Chemotherapy for First-Line Treatment of Metastatic Colorectal Cancer

01/23/2024

Featuring Thierry André, MD

Thierry Andre, MD, discusses the...

01/23/2024

Oncology

Videos

Circulating Tumor DNA-Guided vs Standard Management of Locally Advanced Rectal Cancer

01/20/2024

Featuring Jeanne Tie, MBChB, MD

Featuring Jeanne Tie, MBChB, MD ...

Professor Jeanne Tie, MBChB,...

01/20/2024

Oncology

Interactive Features

Quiz

Quiz: Incidence of Anal Cancer

05/18/2023

By approximately how much has the incidence of anal cancer has increased per year?

By approximately how much has...

05/18/2023

Oncology

Test Your Knowledge

Quiz: Does Pembrolizumab Plus CRT After FOLFOX Provide Benefit for LARC?

09/03/2021

True or false: Data from the NRG-GI002 trial show that neoadjuvant pembrolizumab plus CRT after FOLFOX treatment provides significant benefit as a combination therapy for patients with LARC.

True or false: Data from the...

09/03/2021

Oncology

Quiz

Quiz: Which Therapy Enhances Tumor Immunologic Response in LARC?

08/09/2021

Which therapy was found to enhance tumor immunologic response in patients with LARC?

Which therapy was found to...

08/09/2021

Oncology

Test Your Knowledge

Quiz: Single Agent Vs Combo Therapy for Cetuximab in CRC, Head and Neck Cancer

04/22/2021

True or False: Cetuximab, a novel dosing regimen recently approved by the FDA, can be dosed alone or in combination with chemotherapy for patients with either colorectal or head and neck cancer.

True or False: Cetuximab, a...

04/22/2021

Oncology

Test Your Knowledge

Quiz: Does Coffee Consumption Yield Benefit in CRC?

04/05/2021

True or False: Several compounds found in coffee possess antioxidant, anti-inflammatory, and insulin-sensitizing effects, which may contribute to anticancer activity.

True or False: Several compounds...

04/05/2021

Oncology

Test Your Knowledge

Quiz: What Are the 3 Current Modalities for Rectal Cancer?

03/24/2021

Which of the following are the 3 current modalities for rectal cancer?

Which of the following are the 3...

03/24/2021

Oncology

Test Your Knowledge

Quiz: Anlotinib Therapy for Chinese Patients with Mutated CRC

01/28/2021

True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.

True or false: Anlotinib has...

01/28/2021

Oncology

Test Your Knowledge

Quiz: Is Differentiating Tumor Tissue from Pure Fibrosis Possible During Surgery for CRC?

08/21/2020

True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.

True or false: Classifying and...

08/21/2020

Oncology

Test Your Knowledge

Quiz: Is Oxaliplatin Superior to Mitomycin C During HIPEC for Colorectal Peritoneal Metastases?

07/31/2020

True or false: Overall survival disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for colorectal peritoneal metastases.

True or false: Overall survival...

07/31/2020

Oncology

Test Your Knowledge

Quiz: Can Plasma MDMs Accurately Detect Distant Recurrent CRC?

06/22/2020

True or False: MDMs in plasma show promise as a method for accurately detecting distant recurrent CRC.

True or False: MDMs in plasma...

06/22/2020

Oncology

Recent News

News

Neoadjuvant Nivolumab Plus Ipilimumab Showed Promise Among Patients With Locally Advanced Mismatch-Repair Deficient Colon Cancer

07/18/2024

Stephanie Holland ;

According to results from the phase 2 NICHE-2 trial, neoadjuvant nivolumab plus ipilimumab showed promise among patients with locally advanced mismatch repair-deficient colon cancer.

According to results from the...

07/18/2024

Oncology

News

Lenvatinib Plus Pembrolizumab Did Not Significantly Improve Overall Survival Among Patients With pMMR or Not MSI-High Metastatic Colorectal Cancer

07/11/2024

Stephanie Holland ;

Final analysis results from the...

07/11/2024

Oncology

News

FDA Grants Accelerated Approval to Adagrasib With Cetuximab for Patients With KRAS G12C-Mutated Colorectal Cancer

06/21/2024

Based on results from the KRYSTAL-1 trial, the FDA has granted accelerated approval to adagrasib with cetuximab for patients with KRAS G12C-mutated colorectal cancer.

Based on results from the...

06/21/2024

Oncology

News

Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors

05/17/2024

Stephanie Holland

Results from the ORANGE II PLUS...

05/17/2024

Oncology

News

Potential Benefits From Neoadjuvant Chemotherapy for Patients With Locally Advanced Colon Cancer

04/09/2024

Stephanie Holland

Results from the phase 3 OPTICAL study found potential benefits from neoadjuvant mFOLFOX6 or CAPOX among patients with locally advanced colon cancer.

Results from the phase 3 OPTICAL...

04/09/2024

Oncology

News

FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-Positive Solid Tumors

04/08/2024

Stephanie Holland

The FDA granted accelerated...

04/08/2024

Oncology

News

FDA Grants Approval to Fruquintinib for Patients With Refractory Metastatic Colorectal Cancer

11/10/2023

Allison Casey

On November 8, 2023, the FDA approved fruquintinib for the treatment of patients with metastatic colorectal cancer who had previously been treated with multiple chemotherapies, an anti-VEGF therapy, and, if necessary, an anti-EGFR therapy.

On November 8, 2023, the FDA...

11/10/2023

Oncology

News

Effect of HER2 Overexpression or Amplification on Resistance to Anti-EGFR Treatment Among Patients with RAS Wild-Type Metastatic Colorectal Cancer

08/10/2023

Allison Casey

According to a systemic review and meta-analysis, patients with HER2-positive, RAS wild-type metastatic colorectal cancer who were treated with anti-EGFR therapies were more likely to have worse progression-free survival and response than...

According to a systemic review...

08/10/2023

Oncology

News

Second-Line Avelumab Improved PFS and Disease Control Among Patients With dMMR/MSI Metastatic Colorectal Cancer

08/10/2023

Allison Casey

According to a phase 2 trial, avelumab had better efficacy and tolerability among patients with deficient mismatch repair and/or microsatellite instability metastatic colorectal cancer compared with standard-of-care chemotherapy.

According to a phase 2 trial,...

08/10/2023

Oncology

News

FDA Approval of Trifluridine and Tipiracil With Bevacizumab for Patients With Previously Treated Metastatic Colorectal Cancer

08/02/2023

Allison Casey

On August 2, 2023, the FDA granted approval to trifluridine and tipiracil plus bevacizumab for the treatment of patients with previously treated metastatic colorectal cancer.

On August 2, 2023, the FDA...

08/02/2023

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology